SHENZHEN, China, 7 May 2019 – MGI Tech Co., Ltd. (MGI) and Genoks, a leading Turkish provider of genetic sequencing platforms and kits, announced an exclusive collaboration on Whole Exome Sequencing (WES) tests. These tests will be conducted on MGI’s MGISEQ-2000 platform at the Genoks Genetic Disease Diagnostic Center.
Under the agreement, Genoks will contribute regional expertise and distribution capabilities, while MGI will provide its genomic platforms and bioinformatics support. The partnership aims to enhance detection of genetic abnormalities and improve healthcare outcomes in Türkiye and other European countries.
Eren Akdeniz, Managing Partner of Genoks, stated, “Our mission is to leverage genomics expertise to advance life science research and improve human health.” Genoks Chairman Ozden Bostan reaffirmed the commitment to a long-term collaboration with MGI.
Duncan Yu, President of MGI, commented, “MGI’s advanced technology enables high-throughput next-generation sequencing to support life science research, medicine and healthcare. We are pleased to collaborate with Genoks to bring these capabilities to Turkish customers and anticipate meaningful improvements in healthcare outcomes.”
About MGI
MGI Tech Co., Ltd. develops sequencing devices, consumables and multi-omics platforms to support life science research, medicine and healthcare. Its proprietary technology underpins a mission to deliver effective, affordable and comprehensive healthcare solutions worldwide.
About Genoks
Founded in 2008 as an R&D laboratory, Genoks provides strategic and technical support to public and private health institutes, aiming to expand the clinical genetic testing market across Türkiye and neighbouring regions.
Contacts
MGI Tech Co., Ltd.
Building 11, Beishan Industrial Zone, Yantian District
518083 Shenzhen, China
www.mgitech.cn
Genoks Genetic Diseases Diagnostic Center
Aziziye Mahallesi, Cinnah Caddesi, No: 64/B
06690 Cankaya, Turkey
www.genoks.com.tr
